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The $1000 genome may still be years away, but with the arrival of next-generation sequencing 
(NGS) technologies that are much faster and cheaper than the traditional Sanger method, large-
scale sequencing of hundreds or even thousands of human genomes is fast becoming reality.Sequencing of the 3 billion base pairs 
of the human genome took 3 to 4 years 
using conventional Sanger sequenc-
ing machines and cost about $300 mil-
lion. But the commercial availability 
of next-generation sequencing (NGS) 
 technologies that are up to 200 times 
faster and cheaper than conventional 
Sanger machines is spawning a flurry of 
ambitious new sequencing projects. “A 
drop in price of 200-fold doesn’t hap-
pen very often,” says geneticist George 
Church of Harvard Medical School. 
Church is cofounder of Knome, which 
announced in November last year that 
it would offer sequencing of a whole 
human genome for $350,000. Church 
has also started the “personal genome 
project,” which aims to sequence rel-
evant regions of the genomes of 100,000 
people over the next two years.
In January, an international consor-
tium that includes the National Institutes 
of Health announced the 1,000 Genomes 
Project, which aims to sequence the 
genomes of 1,000 people worldwide 
including individuals from Africa, Japan, 
China, the US, and Italy. “Such a project 
would have been unthinkable only two 
years ago,” says Richard Durbin of the 
Wellcome Trust Sanger Institute in the 
UK, which is part of the consortium. The 
Beijing Genomics Institute in Shenzhen, 
China, another participant in the 1,000 
Genomes Project, has started its own 
initiative to sequence the genomes of 
100 Chinese people. And Craig Venter, 
founder and president of the J. Craig Ven-
ter Institute in Rockville, Maryland, says 
his institute plans to use the new tech-
nologies to sequence between 10 and 
50 human genomes over the next year 
and up to 10,000 over the next 10 years. 
Finally, a few weeks ago, a company 
called Pacific Biosciences announced 
that it is working on a next-generation 
sequencing instrument that ultimately 
will be capable of sequencing a diploid human genome at 1-fold (1×) coverage 
in about 4 min. The company plans to 
start selling a first-generation version of 
the system by 2010. The race is now on 
for cheaper and faster DNA sequencing 
technologies capable of handling an ever 
greater number of human genomes.
Shopping for Hardware
Several companies have commercially 
available NGS platforms. 454 Life Sci-
ences, now owned by Roche, started 
selling its NGS sequencing machines 
in 2005. Next came Illumina’s Genome 
Analyzer, which became commercially 
available in January 2007. And in Octo-
ber last year, Applied Biosystems (ABI) 
formally launched their NGS sequencer. 
A fourth company, Helicos  BioSciences, 
announced last month that it received its 
first order. 
Other than buying a commercial plat-
form, users also have the option to build 
their own NGS system using compo-
nents provided by George Church, in an 
open-source approach Church likens to 
the Linux operating system. According 
to Church, building such a system costs 
about $120,000, or about a quarter the 
cost of most of the commercially avail-
able NGS platforms.
Most NGS technologies eliminate 
the bacterial cloning step used in tradi-
tional Sanger sequencing and instead 
amplify single isolated DNA molecules 
and analyze them in a massively paral-
lel way. Hundreds of thousands or even 
tens of millions of single-stranded DNA 
molecules are immobilized on a solid 
surface like a glass slide or on beads. In 
the case of 454, single DNA strands are 
attached to beads and then amplified by 
PCR in separate water droplets in oil for 
each DNA-loaded bead, such that there 
is a separate PCR and resulting clone for 
each DNA strand. The beads are then 
mixed with DNA polymerase and depos-
ited in plates containing more than 1 mil-Cell lion wells with one bead per well. Nucle-
otides then flow sequentially over the 
wells, and as each nucleotide is added 
to form complementary DNA strands, 
pyrophosphate is released and detected 
in a chemiluminescent flash.
The NGS platforms differ in several 
ways, such as read length and the num-
ber of DNA molecules they sequence in 
parallel. Traditional Sanger sequencing 
machines analyze terminally labeled DNA 
strands and can read about 800 bases 
of 100 DNA molecules simultaneously. In 
contrast, the NGS platforms read many 
more DNAs in parallel but have shorter 
read lengths. For example, 454’s GS 
FLX machine reads 400,000 DNAs that 
are each about 250 bases in length; 
Illumina’s Genome Analyzer and ABI’s 
SOliD platform can read tens of millions 
of DNAs up to about 35–50 bases in 
length. These three NGS platforms also 
differ in cost per base: the 454 machine 
sequences are about ten times cheaper 
than traditional Sanger technology, and 
Illumina and ABI are 100 times cheaper, 
says Steven Jones, head of bioinformat-
ics at the Genome Sciences Centre in 
Vancouver, Canada.
Forging New Research Paths
NGS technologies have made a vari-
ety of ambitious sequencing projects 
feasible. Sequencing the Neanderthal 
genome has been “made possible totally 
by the high throughput sequencing tech-
nologies,” says Svante Pääbo of the Max 
Planck Institute for evolutionary anthro-
pology in Leipzig, Germany, who heads 
the project. A big challenge is that only 
1%–6% of the DNA in ancient Neander-
thal bones is Neanderthal, the remaining 
DNA is from bacterial contamination. “I 
think the key with 454 is that it’s actually 
PCR of a single isolated DNA molecule 
on a bead,” Pääbo says. This, he points 
out, gives even rare DNAs a chance to 
be detected. “The polymerase has to 132, March 7, 2008 ©2008 Elsevier Inc. 721
work with the one molecule that is there,” 
Pääbo says. With traditional sequencing, 
the DNAs would have to be amplified 
first in a mixture, competing with millions 
of nonhuman DNAs.
The 454 sequencer, with its relatively 
long reads of about 250 bases, “is the 
ideal read length for ancient DNA,” 
Pääbo says. That is because it takes 
at least 30 base pair long high-quality 
reads to ensure that bacterial sequences 
do not show up as apparent matches 
with human sequences. In 2006, Pää-
bo’s group reported the sequence of 1 
million bases of Neanderthal DNA after 
sifting through a total number of 20 mil-
lion bases. Pääbo  has calculated that it 
will take 2,000 runs on a 454 machine to 
get 1× coverage of the full Neanderthal 
genome. Pääbo says he is ready to pub-
lish 1%–2% of the Neanderthal genome 
sequence soon using the original Nean-
derthal specimen from Croatia, as well 
as two additional specimens discovered 
in Germany and Spain.
The relatively longer reads of the 
454 platform are also the choice for 
sequencing regions of bacterial 16S 
rRNA genes to study bacterial diversity. 
Mitchell Sogin of the Woods Hole Marine 
Biological Laboratory says he uses 454 
because he needs a stretch of at least 
100 bases to reliably determine how 
a sequence is related to known bacte-
rial rRNA sequences. “We need to have 
on the order of 100 base pairs of con-
tinuous information to make this work,” 
Sogin says. He notes that for his analy-
ses, sequencing with 454 is about 100 
times cheaper than traditional sequenc-
ing. In 2006, for example, he sequenced 
130,000 16S rRNA genes from sea water 
and found that one liter contains at least 
25,000 different kinds of microbes. Rob 
Knight at the University of Colorado also 
uses 454 machines to sequence frag-
ments of bacterial 16S rRNA genes. 
Among other sequencing projects, 
Knight is collaborating with Jeffrey Gor-
don of Washington University in St. Louis 
to compare bacterial diversity in the guts 
of obese and nonobese twins. The idea 
is to use twins to untangle diet and envi-
ronmental factors from each other and 
from genetic factors, Knight says. “The 
goal is to get twins that are concordant 
and discordant for obesity and [look at] 
systematic changes.”722 Cell 132, March 7, 2008 ©2008 Elsevier Whereas 454's longer reads are the 
best choice for some research projects, 
the shorter read lengths generated by the 
Illumina machines work better for other 
projects, such as combining sequenc-
ing with chromatin immunoprecipitation 
(ChIP) assays in which DNA molecules 
bound by proteins are isolated with anti-
bodies. Until recently, these DNA pieces 
were analyzed by hybridization to DNA 
probes on microarray chips (called ChIP-
chip). But several recent studies instead 
use Illumina's NGS platform to sequence 
and count all of the isolated DNAs in a 
new approach dubbed ChIP-Seq. Keji 
Zhao of the National Heart, Lung, and 
Blood Institute in Bethesda, Maryland, 
and his group used ChIP-Seq for the 
first human genome-wide mapping of 
20 different types of histone modifica-
tions. Illumina's machines are ideal for 
ChIP-Seq because they can read about 
30 million DNAs per run, says Zhao, 
whereas 454 only sequences several 
hundred thousand DNAs per run. “The 
most important feature we need is the 
sequence tag number,” Zhao says. “We 
just need 25 base pairs to identify [any 
unique] sequence in the genome.”
ChIP-Seq is an example of an NGS appli-
cation that only requires  resequencing 
(instead of de novo sequencing) of genes 
that are already mapped to a sequenced 
and assembled genome. Shorter read 
lengths are sufficient for such applica-
tions because the reads only need to be 
long enough to find a unique match in 
the assembled genome. But NGS read 
lengths are not long enough for de novo 
sequencing projects because it is too 
difficult to assemble the shorter reads, 
and so traditional Sanger sequencing 
still has its place. “There is no question 
that, today, one cannot assemble human 
genomes as effectively by using the new 
methods, as can be achieved by using 
the Sanger technology,” says Jeffery 
Schloss of the National Human Genome 
Research Institute. Eric Lander, director 
of the Broad Institute of MIT and Harvard 
University, agrees. The new sequencing 
technologies do not have the ability right 
now to assemble a mammalian genome, 
he says.
But at least with 454, it is possible 
to do de novo assembly of bacterial 
sequences, points out Chad Nusbaum, 
codirector of the genome sequenc-Inc.ing and analysis program at the Broad 
Institute in Cambridge, Massachusetts. 
“When you sequence a bacterium by 
traditional methods, you do 6–8× cov-
erage and you get a really good assem-
bly,” Nusbaum says, adding that with 
the 454 sequencer, about 15× cover-
age is needed to get good assembly. 
Because of the required additional 
coverage, 454 is probably less than ten 
times cheaper than traditional Sanger 
sequencing, Nusbaum points out. And 
with the even shorter reads of the Illu-
mina machine, de novo assembly is 
not yet possible but should be soon, 
he adds. Nusbaum is combining tra-
ditional sequencing with the 454 and 
Illumina platforms to sequence de novo 
the genome of the bacterial pathogen 
Listeria monocytogenes.
Next-Generation Sequencing Gets 
Personal
In October 2006, the X Prize Foundation 
announced a $10 million prize for the first 
team to sequence 98% of 100 human 
genomes at 99.999% accuracy over a 10 
day period for $10,000 per genome. The 
current technologies are nowhere near 
that, Venter says. “I don’t think any of the 
existing commercial technologies have a 
chance of winning the X Prize,” empha-
sizes Venter, co-chair of the scientific 
advisory board for the genomics X Prize.
“The current cost to sequence a 
human genome is hundreds of thou-
sands of dollars,” says David Altshuler 
of the Broad Institute. And Lander 
points out that “the $1,000 genome 
is going to take another generation or 
beyond.” Others are more optimistic. 
With next-next-generation sequenc-
ing technologies such as nanopore 
sequencing on the horizon, some say 
that the $1,000 genome is less than ten 
years away. “If you just graph things 
statistically, it’s going to happen within 
five years,” Venter says. That price will 
put the sequencing of an entire genome 
within everybody’s reach, emphasizes 
Church. “Suddenly, millions of people 
can afford to get their own genome 
analyzed and correlations with medi-
cal and non-medical traits explored,” 
Church says, adding that there will be 
a lot to sequence. “There are 6 billion 
humans and each of them has 6 billion 
base pairs,” he says. Church believes 
that most of these sequencing efforts 
will be for resequencing, using the blue-
print of the assembled human genome 
for comparison.
Still, it may be too soon to focus on 
resequencing without obtaining more 
detailed de novo sequences of more 
than just a few individual humans, says 
Venter. We still do not know enough 
about how much variation there is 
between individual human genomes, 
he adds. To improve the quality of the 
available draft sequence, Venter has 
used the more accurate, longer reads of 
the traditional Sanger sequencers. He 
recently published an improved draft of 
his own genome sequence, with 99% 
coverage of both sets of chromosomes. 
Given the variations between genomes, 
it is also important to compare many 
people to be able to tell which variations 
are the relevant ones, says Lander. “The 
real way that you end up doing this is 
you look at many people and then you 
say aha, I am seeing a mutation in the 
same gene.”
A SNP at the Price?
NGS technologies are also being used 
to confirm and extend associations 
between single nucleotide polymor-
phisms (SNPs), identified in genome-
wide association studies, and certain 
diseases. More than 100 associations 
have been identified so far for a variety 
of diseases including rheumatoid arthri-
tis, prostate cancer, and type 1 and 2 
diabetes. The Broad Institute’s Altshuler 
leads one of the groups that have iden-
tified ten associations between SNPs 
and diabetes type 2. Until now, these 
studies used microarrays that tested 
patients for SNPs largely derived from 
the HapMap project, which has identi-
fied millions of SNPs across the human 
genome. The big challenge is to find the 
biologically relevant variations that are 
the underlying cause of disease. To do 
this, Altshuler is using the Illumina NGS 
platform to “deep sequence” the regions 
around the SNPs associated with type 2 
diabetes in hundreds of people with and 
without the disease. “We are sequencing lots of people around these diabetes loci 
to figure out not just the common SNPs 
but rare [variations] as well to get a fuller 
picture of how [they] are actually altered 
to affect disease,” Altshuler says. “In 
almost no cases do we know the actual 
causal genetic change.” This means 
using sequencing to find every possible 
variation to recognize mutations that 
cause the disease, he says. In another 
approach, Jeremy Edwards of the Uni-
versity of New Mexico in Albuquerque 
is planning to use NGS to sequence the 
entire chromosome 6 of several thou-
sand melanoma patients. “We will try 
to uncover new SNPs that are related 
to poor survival in people that get mela-
noma,” Edwards says.
Altshuler notes that additional sequenc-
ing results will also be used to improve 
currently available SNP arrays. “What’s 
going to happen is that hundreds or thou-
sands of people will be sequenced in the 
coming years because the technology 
makes it possible,” Altshuler says, “and 
those SNP chips will then be upgraded 
to have all the common genetic varia-
tions on them.” Eventually, sequencing 
will replace SNP chips, but only when 
it becomes cheap enough. Currently, it 
costs hundreds of dollars to test one mil-
lion SNPs, Altshuler says, much less than 
the hundreds of thousands of dollars to 
sequence a human genome. “If you could 
sequence people with great accuracy 
and at a cost that was hundreds of dollars 
then I am sure it will replace the genotyp-
ing,” Altshuler says.
With his “personal genome project,” 
Church hopes to sequence 1% of the 
genomes of 100,000 people over the 
next two years. “That’s the sort of num-
ber that you need in order to get statisti-
cal significance,” he says. The project will 
correlate genetic information with physi-
cal characteristics and medical traits, 
and the sequencing will focus on coding 
regions. “About 95 percent of trait-affect-
ing mutations impact coding regions,” 
says Church. The first ten volunteers have 
enrolled and given blood, saliva, and skin 
tissue samples, and enrollment of the 
general public will begin soon.Cell A Glimpse of the Future
So what will sequencing look like in the 
future? Both companies and academic 
groups are working on next-next-
generation sequencing technologies. 
Nanopore sequencing, for example, 
measures the change in current as a 
single DNA molecule is pulled through a 
tiny pore. This approach could achieve 
long read lengths, says David Deamer 
of the University of California at Santa 
Cruz, who is developing nanopore 
sequencing. “We can pull DNA that’s 
several thousand bases long through 
a pore,” he says. Deamer predicts 
that the sequencing devices should 
be quite cheap, in the range of several 
thousand dollars in larger production 
runs, and nanopore sequencing could 
also save costs for sample prepara-
tion, as the only step will be purifying 
the DNA, without the need for amplifi-
cation. His group is using natural nano-
pores made of a bacterial protein, and 
others are using artificial nanopores to 
pull through the DNA strands. Deamer 
expects that sequencing with nanop-
ores will be demonstrated in about a 
year, although surpassing the speed of 
the current NGS platforms is still sev-
eral years away. “We are aiming for the 
$1,000 genome,” Deamer says.
Still, it remains unclear who will win 
the race for the $1,000 genome, or the 
X Prize, for that matter. But as Lander 
points out, “Race implies that the first 
person over a finish line wins, but that’s 
not how science is done,” he says. “It’s 
a never ending progression.” Lander 
adds that as sequencing technology 
improves, it will be possible to use it 
for increasingly demanding tasks. After 
ChIP-Seq, “the next simplest prob-
lem is mutation detection,” Lander 
says. “The hardest problem is de novo 
assembly. Everybody is working up 
that chain right now.” Lander, for his 
part, says that he does not have any 
favorite technology. “I see potential 
advantages in all of these,” he says. 
“Science will be served by the diversity 
of approaches. All of these [will] con-
tribute to progress. Keep it coming.”
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